drugset
drugset / Trial / NCT00052780

Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors

NCT00052780 ↗

Phase 1 Completed 72 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the safety of combining O6-benzylguanine with temozolomide in treating children who have recurrent or refractory brain tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. O6-benzylguanine may increase the effectiveness of temozolomide by making tumor cells more sensitive to the drug.

Timeline

Start
2002-10
Primary completion
2007-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject O6-benzylguanine Small molecule — Intravenous
Subject Temozolomide Small molecule — Oral
Subject filgrastim Protein / enzyme biologic — Subcutaneous

Indications

benign meningioma childhood brain stem glioma childhood central nervous system germ cell tumor childhood cerebellar astrocytic neoplasm childhood cerebral astrocytoma childhood choroid plexus neoplasm childhood medulloblastoma childhood oligodendroglioma craniopharyngioma ependymoblastoma grade II meningioma grade III meningioma medulloepithelioma mixed glioma optic pathway glioma pediatric infratentorial ependymoma pediatric supratentorial ependymoma pineoblastoma subependymal giant cell astrocytoma supratentorial primitive neuroectodermal tumor